UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2018

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of Incorporation)

001-35518

(Commission File Number)

1550 East Gude Drive, Rockville MD (Address of principal executive offices)

20-2590184 (IRS Employer Identification No.)

> **20850** (Zip Code)

Registrant's telephone number, including area code: (301) 838-2500

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events.

On November 7, 2018, Supernus Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company's management will present an overview and Company update as well as host investor meetings, at the Stifel 2018 Healthcare Conference in New York, NY on November 13, 2018; the Jefferies 2018 London Healthcare Conference in London, U.K. on November 15, 2018; and the Piper Jaffray 30th Annual Healthcare Conference in New York, NY on November 27, 2018. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:

Exhibit 99.1 – Press Release Dated November 7, 2018.

EXHIBIT INDEX

Number	D	escription	
99.1	Press Release Dated November 7, 2018.		Attached
		3	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUPERNUS PHARMACEUTICALS, INC.

DATED: November 8, 2018

By: /s/ Gregory S. Patrick

Gregory S. Patrick Vice-President and Chief Financial Officer



Supernus to Present at Three November Healthcare Conferences

ROCKVILLE, Md., November 7, 2018 — Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and Company update as well as host investor meetings, at the following three conferences:

Stifel 2018 Healthcare Conference Date: Tuesday, November 13, 2018 Time: 3:30 p.m. EST Place: Lotte New York Palace Hotel, New York

Jefferies 2018 London Healthcare Conference Date: Thursday, November 15, 2018 Time: 2:40 p.m. GMT (9:40 a.m. EST) Place: Waldorf Hilton, London, U.K.

Piper Jaffray 30th Annual Healthcare Conference Date: Tuesday, November 27, 2018 Time: 12:00 p.m. EST Place: Lotte New York Palace Hotel, New York

Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.

A live webcast of the respective presentations can be accessed by visiting 'Events & Presentations' in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of these webcasts will be available for 60 days after the respective conferences on the Company's website.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR[®] (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR[®] (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients, SPN-812 for the treatment of ADHD and Oxtellar XR for the treatment of bipolar disorder.

CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc.

Or

Investor Contact: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: peter.vozzo@westwicke.com